Long
$BVXV Overreaction to Phase 3 Trial Anticipating $20 PT
Dropped from $40 to $3 on Phase 3 trial failure wasn’t even an FDA denial. Has facilities and will be focusing on other trials. Total overreaction. PT $20+
The study’s primary safety endpoint was also met.
The study’s primary safety endpoint was also met.
Related publications
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
Related publications
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.